Fayaz Shima, Karimmirza Maryam, Tanhaei Shokoofeh, Fathi Mozhde, Torbati Peyman Mohammadi, Fard-Esfahani Pezhman
Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran E-mail :
Asian Pac J Cancer Prev. 2014 Jan;14(11):6727-31. doi: 10.7314/apjcp.2013.14.11.6727.
Homologous recombination (HR) repair has a crucial role to play in the prevention of chromosomal instability, and it is clear that defects in some HR repair genes are associated with many cancers. To evaluate the potential effect of some HR repair gene polymorphisms with differentiated thyroid carcinoma (DTC), we assessed Rad51 (135G>C), Rad52 (2259C>T), XRCC2 (R188H) and XRCC3 (T241M) polymorphisms in Iranian DTC patients and cancer-free controls. In addition, haplotype analysis and gene combination assessment were carried out. Genotyping of Rad51 (135G>C), Rad52 (2259C>T) and XRCC3 (T241M) polymorphisms was determined by PCR-RFLP and PCR-HRM analysis was carried out to evaluate XRCC2 (R188H) . Separately, Rad51, Rad52 and XRCC2 polymorphisms were not shown to be more significant in patients when compared to controls in crude, sex-adjusted and age-adjusted form. However, results indicated a significant difference in XRCC3 genotypes for patients when compared to controls (p value: 0.035). The GCTG haplotype demonstrated a significant difference (p value: 0.047). When compared to the wild type, the combined variant form of Rad52/XRCC2/XRCC3 revealed an elevated risk of DTC (p value: 0.007). It is recommended that Rad52 2259C>T, XRCC2 R188H and XRCC3 T241M polymorphisms should be simultaneously considered as contributing to a polygenic risk of differentiated thyroid carcinoma.
同源重组(HR)修复在预防染色体不稳定方面起着至关重要的作用,并且很明显,一些HR修复基因的缺陷与许多癌症相关。为了评估某些HR修复基因多态性对分化型甲状腺癌(DTC)的潜在影响,我们对伊朗DTC患者和无癌对照者评估了Rad51(135G>C)、Rad52(2259C>T)、XRCC2(R188H)和XRCC3(T241M)多态性。此外,还进行了单倍型分析和基因组合评估。通过PCR-RFLP确定Rad51(135G>C)、Rad52(2259C>T)和XRCC3(T241M)多态性的基因分型,并通过PCR-HRM分析评估XRCC2(R188H)。单独来看,在未经调整、性别调整和年龄调整的形式下,与对照组相比,患者的Rad51、Rad52和XRCC2多态性没有显示出更显著的差异。然而,结果表明,与对照组相比,患者的XRCC3基因型存在显著差异(p值:0.035)。GCTG单倍型显示出显著差异(p值:0.047)。与野生型相比,Rad52/XRCC2/XRCC3的联合变异形式显示DTC风险升高(p值:0.007)。建议将Rad52 2259C>T、XRCC2 R188H和XRCC3 T241M多态性同时视为分化型甲状腺癌多基因风险的影响因素。